Critical review: assessment of interferon-β immunogenicity in multiple sclerosis

Klaus Bendtzen

    13 Citationer (Scopus)

    Abstract

    This review discusses type I interferon (IFN) immunogenicity with focus on methods of detection of anti-IFN antibodies in patients treated with human recombinant IFN-β. Pitfalls involved in the clinical use of various types of assays for binding antibodies and neutralizing antibodies against IFN-β are presented, and the widely held distinction between binding antibodies and neutralizing antibodies is questioned both in terms of detection and clinical importance. The article also addresses important bioavailability and pharmacokinetic issues occurring with prolonged use of protein drugs. The rationale for individualized or personalized medicine, ie, optimizing therapies according to individual needs rather than using standardized trial-and-error regimens to all patients, is highlighted.
    OriginalsprogEngelsk
    TidsskriftJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
    Vol/bind30
    Udgave nummer10
    Sider (fra-til)759-66
    Antal sider8
    DOI
    StatusUdgivet - 1 okt. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Critical review: assessment of interferon-β immunogenicity in multiple sclerosis'. Sammen danner de et unikt fingeraftryk.

    Citationsformater